Sean McClain
Founder, CEO, President & Director
Good morning, everyone. Thank you for joining our deep dive today into ABS-201. At Absci, our mission is to use generative AI to create better biologics for patients who don’t have good enough options today. We talk a lot about our platform, our lab-in-the-loop, and our ability to create better biologics faster. But today isn’t just about the platform in the abstract, today is about the results. ABS-201, which we believe could be a paradigm-changing therapeutic for androgenic alopecia.
Now historically, the biopharma industry has dismissed hair loss as just cosmetic. But when you speak to patients, you realize that characterization is deeply flawed. For tens of millions of people, both men and women, this is not about vanity. It’s about identity. It’s about mental health and the profound loss of confidence that impacts their daily lives.
Despite this massive unmet medical need, the standard of care has remained stagnant for decades, we’re relying on old mechanisms that often come with difficult trade-offs. This is why we’re so excited about ABS-201, by leveraging our AI drug creation platform, we have
